Integra LifeSciences Corporation

5 days ago · zacks.com

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

6 days ago · seekingalpha.com

Integra LifeSciences Holdings Corporation (IART) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

25 days ago · zacks.com

Integra (IART) reported earnings 30 days ago. What's next for the stock?

26 days ago · zacks.com

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 month ago · zacks.com

Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.

1 month ago · zacks.com

Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.

2 months ago · zacks.com

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2 months ago · seekingalpha.com

Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

2 months ago · marketbeat.com

Integra LifeSciences NASDAQ: IART reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, exceeding the company's guidance range.